HALO stock news · Halozyme Therapeutics Inc.
Get alerts for HALO
Follow Halozyme Therapeutics Inc. (HALO) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for HALOThe Nasdaq 100 jumped 2% after a strong jobs report, with chipmakers like AMD and Micron recovering.
NeutralHalozyme’s third-quarter results beat estimates by a small amount, and an analyst cut its rating. These mixed reports do not show a clear change in the company’s business outlook.
Halozyme Therapeutics' sales jumped 39.2% last quarter, and the company raised its full-year forecast.
Good for HALOHalozyme's Q3 sales rose 39% to $493 million, and it raised its full-year sales and profit forecasts. These gains point to a stronger outlook for the company.
Halo Minerals PLC shares a new presentation for investors and says it will hold a webinar.
Good for HALOHalo Minerals shared estimates for its Chile copper-waste project, including 33.9 million tonnes of reserves and about US$196 million in estimated after-tax value. This is favorable for the company.
Halo Minerals PLC shared a new presentation for investors and said it will hold a webinar.
Good for HALOHalo Minerals reports estimates of 83,626 tonnes of copper and US$195.9 million in after-tax project value at Playa Verde. This supports its outlook, though the mine is still being developed.
Halozyme Therapeutics has new board member James Daly, who will serve until the 2029 stockholder meeting.
NeutralHalozyme elected James Daly to its board and will pay him under its standard director plan. The filing reports no business change, so it does not alter the company's outlook.
Halozyme Therapeutics, Inc. has signed an important agreement about convertible notes.
Bad for HALOHalozyme filed 1.50% convertible notes that could convert into up to 13,676,100 shares; I view this as bearish because it creates potential dilution.